Full TitleAn Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL)
The purpose of this study is to assess the safety and effectiveness of the medication tirabrutinib in people with primary central nervous system lymphoma (PCNSL) that has come back or continued to grow despite treatment. Tirabrutinib blocks a protein called BTK, which some cancer cells need to grow and survive. Blocking BTK may slow or stop PCNSL growth. It is a tablet that is taken orally (by mouth).
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have PCNSL that has come back or continued to grow despite treatment that included methotrexate.
- At least 2 weeks must pass since the completion of radiation therapy, 3 weeks since chemotherapy, and 4 weeks since major surgery and receipt of tirabrutinib.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Christian Grommes at 212-610-0344.